Medication info
Coibes Dil Tablets 300/12.5 mg

Coibes Dil Tablets 300/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›300mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, oval film-coated tablets
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 200807418 · Notified 2008.07.04 · Insurance code 650203000

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This drug is administered once daily, with or without food. Titration to the appropriate dose of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this drug may be administered in combination with other antihypertensive agents. 2. When this drug is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is generally initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this drug as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this drug is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for these patients. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this drug. ○ Patients with hepatic impairment This drug should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary for older adults.
Child dose
Children and adolescents under 18 years: The safety and efficacy of this drug have not been established.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used to control blood pressure in patients with essential hypertension. It is effective even when blood pressure is insufficiently controlled with monotherapy. Additionally, it is used as an initial therapy in patients with moderate or severe hypertension who require combination therapy to achieve target blood pressure. Therefore, this medication helps in managing blood pressure for hypertensive patients.

How to take

Adult dose

This drug is administered once daily, with or without food. Titration to the appropriate dose of each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this drug may be administered in combination with other antihypertensive agents. 2. When this drug is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is generally initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this drug as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this drug is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for these patients. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this drug. ○ Patients with hepatic impairment This drug should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary for older adults.

Child dose

Children and adolescents under 18 years: The safety and efficacy of this drug have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, breastfeeding mothers, and patients who are allergic to this medication or its components should not take it. Patients with severely compromised kidney function or anuria should also avoid this medication. Patients with hypotension, kidney disease, liver disease, heart valve disease, glaucoma, or a history of skin cancer should use this medication with caution. The hydrochlorothiazide component may cause sensitivity to sunlight, so it is important to minimize UV exposure and regularly check skin condition while taking this medication. Side effects such as dizziness, fatigue, nausea, vomiting, abnormal urination may occur; if symptoms are severe, consult a physician. Regular blood tests to check kidney function and electrolyte levels are necessary, especially monitoring potassium level fluctuations. If experiencing symptoms of hypoglycemia or receiving treatment for diabetes, consulting a professional before taking this medication is necessary. Interactions can occur when taken with other antihypertensives, lithium, potassium supplements, non-steroidal anti-inflammatory drugs, so it is crucial to inform healthcare professionals. Safety and efficacy in children and adolescents have not been established; therefore, it is not recommended for them. Elderly patients may have increased sensitivity to this medication, so more caution is needed. In the case of overdose, serious symptoms like hypotension, electrolyte imbalance, dehydration may occur; adherence to the prescribed dosage is critical, and if any unusual symptoms arise, immediate consultation with healthcare professionals is needed. This medication should be kept out of reach of children and stored in its original container to prevent misuse or degradation of quality.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • increased creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 88 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • altered taste
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • kidney function impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • hypotension
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal vascular edema
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disturbances
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • respiratory distress
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • loss of appetite
  • interstitial nephritis
  • renal dysfunction
  • jaundice
  • transient blurred vision
  • xanthopsia
  • weakness
  • muscle spasms
  • anaphylaxis-like reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • erythematosus lupus-like skin reaction
  • reactivation of erythematosus lupus skin
  • photosensitivity reaction
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • increased cholesterol and triglycerides
  • hypoglycemia
  • headache
  • musculoskeletal trauma
  • flushing
  • respiratory infection
  • musculoskeletal pain
  • myalgia
  • cough
  • chest pain
  • dyspepsia
  • heartburn
  • abdominal pain
  • rash
  • anxiety
  • irritability
  • urinary tract infection

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly sealed container to protect it from air and moisture, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius. Doing so helps maintain the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval film-coated tablets

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.